Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Rhea-AI Summary

Cingulate (NASDAQ: CING) updated 4Q25 coverage as Stonegate Capital Partners highlighted progress toward a potential commercial launch of CTx-1301. The NDA remains under FDA review via the 505(b)(2) pathway with feedback focused on manufacturing/CMC, not safety or efficacy.

Following a $12M PIPE in Feb 2026, Cingulate has a pro forma cash balance of ~$23M, which is estimated to provide runway into late 2026; the company also has ATM and ELOC access. The Company discloses a ~1% market share implies ~$250M revenue potential targeting the booster-dose ADHD segment.

Positive

• FDA review limited to manufacturing/CMC, no safety or efficacy concerns
• Completed $12M PIPE in Feb 2026 increasing liquidity
• Pro forma cash of ~$23M provides runway into late 2026
• Ongoing access to capital via ATM and ELOC facilities

Negative

• Runway only extends to late 2026, requiring further financing thereafter
• Regulatory timing may be delayed by manufacturing validation items

News Market Reaction – CING

-4.19%

7 alerts

-4.19% News Effect

+3.9% Peak Tracked

-10.2% Trough Tracked

-$3M Valuation Impact

$77.92M Market Cap

0.1x Rel. Volume

On the day this news was published, CING declined 4.19%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -10.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $77.92M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PIPE financing: $12M Pro forma cash: $23M Runway: late 2026 +4 more

7 metrics

PIPE financing $12M Private investment in public equity completed in February 2026

Pro forma cash $23M Estimated pro forma cash balance after February 2026 PIPE

Runway late 2026 Company-estimated operational cash runway

Market share assumption 1% Illustrative ADHD market share for CTx-1301

Revenue potential $250M Implied revenue at ~1% ADHD market share for CTx-1301

505(b)(2) pathway 505(b)(2) NDA review pathway for CTx-1301 under FDA review

Quarter referenced 4Q25 Stonegate coverage update period for Cingulate

Market Reality Check

Price: $5.96 Vol: Volume 309,171 is below t...

low vol

$5.96 Last Close

Volume Volume 309,171 is below the 738,699 20-day average (relative volume 0.42). low

Technical Price 6.2 is trading above the 200-day MA of 4.82.

Peers on Argus

CING is up 2.16% with 2 peers in momentum also moving up (e.g., PASG +2.74%, CTX...

2 Up 1 Down

CING is up 2.16% with 2 peers in momentum also moving up (e.g., PASG +2.74%, CTXR +1.91%), while HOTH is down 1.99%, indicating both stock-specific and broader biotech dynamics.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	Q4 2025 earnings	Positive	-31.1%	Q4/FY25 results, NDA status, patents, and $12M PIPE financing update.
Feb 17	PIPE financing close	Negative	-3.0%	$12M at-the-market PIPE with lock-up, warrants, and board rights.
Nov 18	3Q25 coverage update	Positive	+1.2%	Stonegate 3Q25 update on NDA acceptance, Phase 3 data, and supply deal.
Nov 13	Q3 2025 earnings	Negative	-12.4%	Q3 results with financing, cash levels, losses, and commercialization plans.
Nov 10	CCO appointment & NDA	Positive	-2.7%	New CCO, NDA acceptance, financing note, and commercial preparations.

Pattern Detected

Recent news with positive operational or regulatory updates often saw negative price reactions, especially around financings and earnings, suggesting a pattern of weak post-news performance despite constructive milestones.

Recent Company History

Over the last several months, Cingulate has advanced CTx‑1301 toward a potential ADHD launch, securing NDA acceptance with a May 31, 2026 PDUFA date, positive Phase 3 data, and multiple financings, including a $12M at‑the‑market PIPE and prior $6M debt funding. Earnings updates showed increasing net loss and limited cash, with runway projected into Q2–Q4 2026. Today’s update from Stonegate again emphasizes regulatory progress and commercialization plans against this backdrop of frequent capital raises and mixed stock reactions.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-03-23

The company has an active shelf registration on Form S-3/A dated 2026-03-23, with the amendment mainly updating auditor consent. The registration is marked effective with 2 recent 424B3 usages, indicating an established mechanism to issue registered securities over time.

Market Pulse Summary

This announcement highlights Stonegate’s 4Q25 update on CTx‑1301, noting that FDA feedback centers o...

Analysis

This announcement highlights Stonegate’s 4Q25 update on CTx‑1301, noting that FDA feedback centers on manufacturing/CMC rather than safety or efficacy, with the NDA under the 505(b)(2) pathway. It underscores a pro forma cash balance near $23M after a $12M PIPE and projected runway into late 2026, alongside ATM and ELOC access. Investors may watch for resolution of remaining CMC items, regulatory timing relative to the May 31, 2026 PDUFA date from prior filings, and future capital-raising activity.

Key Terms

cmc, nda, fda, 505(b)(2) pathway, +2 more

6 terms

cmc medical

"regulatory focus now centered on manufacturing (CMC) rather than clinical performance."

Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

nda regulatory

"The NDA remains under FDA review under the 505(b)(2) pathway"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

fda regulatory

"The NDA remains under FDA review under the 505(b)(2) pathway"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

505(b)(2) pathway regulatory

"The NDA remains under FDA review under the 505(b)(2) pathway"

A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.

pipe financial

"following the $12M PIPE completed in February 2026, the Company has a pro forma cash"

A "pipe" is a planned series of financial transactions or projects that companies intend to carry out over time, often involving the raising of funds or development of new assets. It matters to investors because it provides a clear picture of a company's future growth plans and potential revenue, helping them assess the company's upcoming opportunities and overall stability. Think of it as a detailed roadmap guiding a company's future steps.

adhd medical

"CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now"

Attention-deficit/hyperactivity disorder (ADHD) is a common brain condition that makes it hard for people to focus, control impulses, and sit still—like having a car with strong accelerator and less-effective brakes for attention and activity. For investors, ADHD matters because it drives demand for medications, therapy, digital tools, and education supports, affects workplace productivity and healthcare costs, and is subject to regulatory approvals and insurance coverage decisions that influence market opportunities.

AI-generated analysis. Not financial advice.

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance. The NDA remains under FDA review under the 505(b)(2) pathway, and recent financing, IP progress, and commercial buildout efforts remain supportive of the broader investment thesis. Importantly, following the $12M PIPE completed in February 2026, the Company has a pro forma cash balance of approximately ~$23M, which we estimate provides runway into late 2026. Combined with ongoing access to capital through its ATM and ELOC facilities, we believe Cingulate is positioned to fund ongoing regulatory and manufacturing activities as it works toward resolution of remaining CMC items.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• FDA feedback limited to manufacturing/CMC; no safety or efficacy concerns, positioning remaining work as addressable process validation rather than clinical risk.
• Regulatory timing may shift, but approval remains likely; delay driven by manufacturing validation, not fundamental issues with product profile.
• Large ADHD market opportunity: ~1% share implies ~$250M revenue potential for CTx-1301, primarily targeting the booster-dose segment, as disclosed by the Company.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291352

FAQ

What is the FDA review status for Cingulate's CTx-1301 (CING) as of April 6, 2026?

The NDA for CTx-1301 is under FDA review via the 505(b)(2) pathway, with feedback focused on manufacturing/CMC. According to the company, there are no safety or efficacy concerns and remaining work is process validation rather than clinical risk.

How much cash does Cingulate (CING) have after the February 2026 $12M PIPE and what runway does it provide?

Cingulate has a pro forma cash balance of approximately $23M, which is estimated to fund operations into late 2026. According to the company, additional access to capital via ATM and ELOC supports ongoing regulatory activities.

What does Stonegate say could delay Cingulate's (CING) approval timeline for CTx-1301?

Stonegate notes any delay would likely stem from manufacturing validation (CMC) rather than clinical issues. According to the company, resolving CMC items is expected to be addressable through process validation work.

What revenue potential does Cingulate (CING) attribute to CTx-1301 in the ADHD market?

The company discloses that capturing roughly 1% market share could imply about $250M in revenue, primarily in the booster-dose segment. According to the company, this figure reflects the target opportunity disclosed by management.

How is Cingulate (CING) positioned to fund remaining regulatory and manufacturing activities?

Cingulate combines $23M pro forma cash with access to an ATM and an ELOC to fund near-term needs. According to the company, these financing channels are expected to support work on outstanding CMC items.